PNI was reported prospectively. Although we had already reported that PNI was an important prognostic factor,[19] follow-up time in the previous study was short and the number of patients examined was small. In the present study, all surviving patients were followed for more than five years and the number of examined patients was larger than in our previous study. Moreover, only pT3 or pT4 tumors were examined in the present study, because PNI was not found in pT1 tumors and was rare in pT2 tumors.

PATIENTS AND METHODS

Consecutive patients who underwent curative surgery for pT3 or pT4 colorectal cancer at the National Cancer Center Hospital between May 1997 and Dec 2001 were reviewed. Synchronous or metachronous multiple cancers were excluded from the analysis. One patient who died four days after surgery because of anastomotic leakage and sepsis also was excluded. A total of 509 patients were examined. The patients were followed up at three-month intervals for two years and at six-month intervals thereafter. Tumor markers were examined at every patient visit. CT scans of the liver and lung or abdominal ultrasonography with chest x-ray were performed at least every six months. Colonoscopy was performed twice within five years after surgery. All the surviving patients were followed for more than five years. Fifty-one of 266 patients with Stage III tumors received postoperative adjuvant chemotherapy as part of a clinical trial. Adjuvant radiotherapy was not used for rectal cancer during the study period.

Pathologic Examination

All the specimens were reviewed by two pathologists (TS and YN). Perineural invasion was defined as the presence of cancer cells inside the perineurium in Auerbach's plexus adjacent to the tumor front, and the results and other pathologic findings were described prospectively in the pathology report forms.

Statistical Analysis

Statistical analysis was performed by using the chi-squared test. Survival rates were calculated by the Kaplan-Meier method and survival curves were compared by using the log-rank test. Cox proportional hazards model was used for multivariate analysis. Data differences between groups were considered statistically significant at $P < 0.05$.

RESULTS

PNI and Clinicopathologic Characteristics

A representative case of PNI is shown in Figure 1. Cancer cells invaded the perineurium in Auerbach's plexus. PNI was detected in 132 of 509 patients (26 percent). PNI and clinicopathologic characteristics of the patients are shown in Table 1. PNI was significantly associated with lymph node status, lymphatic invasion, and venous invasion ($P < 0.01$).

PNI in Relation to Recurrence and Survival

In colon cancer, the incidence of liver metastasis in the PNI-positive group was significantly higher than that in the PNI-negative group ($P < 0.01$; Table 2). In rectal cancer, the incidences of liver and lung metastasis and local recurrence in the PNI-positive group were significantly higher than in the PNI-negative group ($P \leq 0.01$). The five-year, disease-free survival rate in the PNI-positive group was 53 percent and that in the PNI-negative group was 80 percent (Fig. 2). Outcome was significantly poorer in the PNI-positive group than in the PNI-negative group ($P < 0.01$). Disease-free survival rates were examined according to tumor site (colon and rectum) and Stage (Stages II and III). Disease-free survival in the PNI-positive group was significantly poorer than that in the PNI-negative group for Stage II and III colon cancer ($P = 0.02$, 0.03, respectively) and Stage III rectal cancer ($P < 0.01$; Table 3, Fig. 3). Although disease-free survival in the PNI-positive group also was poorer than that of the PNI-negative group for Stage II rectal cancer, the difference was not statistically significant ($P = 0.21$). Because 51 of 266 patients with Stage III tumors received adjuvant chemotherapy, which is known to affect survival, the effect of adjuvant chemotherapy on disease-free survival was analyzed (Table 3). Patient survival in the PNI-positive group was poorer than that in the PNI-negative group, irrespective of whether adjuvant chemotherapy was given. Multivariate analysis of PNI, lymph node status, depth of invasion, tumor differentiation, lymphatic invasion, venous invasion, tumor site, preoperative CEA, gender, age, and adjuvant chemotherapy showed that lymph node status, PNI, depth of invasion, and tumor site were significant prognostic factors ($P < 0.01$; Table 4).



Figure 1. Representative PNI. a. Arrows shows cancer cells inside the perineurium in Auerbach's plexus. This is a case of massive PNI. b. Eighty percent of cases of PNI involve only slight invasion to Auerbach's plexus. In this case, one or two plexuses adjacent to the tumor front were invaded by cancer cells (arrow). Arrowhead shows Auerbach's plexus without cancer invasion. PNI = perineural invasion.

DISCUSSION

PNI has been reported to be a prognostic factor in colorectal cancer,[1–5] colon cancer,[20–22] and rectal cancer.[6–17] However, there is still no definitive conclusion about the degree to which PNI is a prognostic factor, especially in colon cancer, because many of the previous studies of PNI were retrospective, and PNI was not clearly defined. Although many of the reports did not define PNI, PNI was considered to be perineural cancer invasion within and outside the bowel wall in some of them,[1,6,9,12] and only extramural PNI was examined in other studies.[7,10,14] We defined PNI as cancer invasion to Auerbach's plexus, and on this basis prospectively examined more than 500 patients. Our findings clearly demonstrated that PNI was a significant prognostic factor in pT3 or pT4 colorectal cancer. Therefore, this study provides strong evidence that cancer invasion to Auerbach's plexus is a prognostic factor for colorectal cancer.

Table 1.
PNI and Clinicopathologic Characteristics of the Examined Patients

	PNI-negative (n=377)	PNI-positive (n=132)	*P* Value
Age (yr)			0.68
<60	155	57	
≥60	222	75	
Male/female ratio	225/152	75/57	0.56
Tumor site			0.16
Colon	229	71	
Rectum	148	61	
Preoperative CEA (ng/ml)			0.34
<5	257	84	
≥5	120	48	
Depth of invasion (pT)			0.08
pT3	329	107	
pT4	48	25	
Lymph node status (pN)			<0.01
pN0	209	34	
pN1	120	57	
pN2	48	41	
Tumor differentiation			0.99
Well/moderate	354	124	
Poor/mucinous	23	8	
Lymphatic invasion			<0.01
Negative	255	37	
Positive	122	95	
Venous invasion			<0.01
Negative	234	53	
Positive	143	79	

PNI = perineural invasion.

The outcome of patients with Stage II colorectal cancer with cancer invasion to Auerbach's plexus was poor, and the survival rate was similar to that of patients with Stage III colorectal cancer. Because adjuvant therapy is recommended for patients with Stage III colorectal cancer, patients with Stage II colorectal cancer with invasion to Auerbach's plexus also are thought to be candidates for such therapy. On the other hand, the outcome of patients with Stage III colon cancer without invasion to Auerbach's plexus was good, and therefore these patients may not require adjuvant chemotherapy. These findings suggest that cancer invasion to Auerbach's plexus could be used to facilitate the selection of patients with colorectal cancer for adjuvant chemotherapy. However, among patients with Stage III colon cancer without invasion to Auerbach's plexus, those who received adjuvant chemotherapy showed better survival than those who did not, although the difference was not statistically significant. Further investigations of cancer invasion to Auerbach's plexus and the need for adjuvant chemotherapy are necessary.

Cancer invasion to Auerbach's plexus is a significant prognostic factor even in patients with colon cancer. Only three studies have examined the relationship between PNI and the prognosis of colon cancer patients.[20–22] These demonstrated that PNI was associated with recurrence and poor survival, although multivariate analysis showed that this association was not significant. Therefore, our study is the first to report a significant association between PNI and survival of colon cancer patients based on multivariate analysis.

Although cancer invasion to Auerbach's plexus is a significant prognostic factor in patients with rectal cancer, the difference in disease-free survival between the PNI-positive group and the PNI-negative group was not statistically significant for Stage II rectal cancer. This may have been the result of the small number of patients with Stage II rectal cancer included in this study (n = 89), and thus any apparent difference would have had low statistical power. Because the difference in five-year, disease-free survival rate between the groups was large (14 percent in this study) and the hazard ratio between the survival curves seemed to be constant over time, statistical significance may have been achieved by analyzing a larger number of patients with Stage II rectal cancer.

Table 2.
Pattern of Recurrence

	PNI-negative	PNI-positive	*P* Value
Colon	n=229	n=71	
Liver	12 (5.2)	14 (19.7)	<0.01
Lung	9 (3.9)	5 (7)	0.28
Peritoneum	6 (2.6)	2 (2.8)	0.93
Local	1 (0.4)	0	0.58
Others	5 (2.2)	1 (1.4)	0.68
Rectum	n=148	n=61	
Liver	9 (6.1)	13 (21.3)	<0.01
Lung	22 (14.9)	18 (29.5)	0.01
Peritoneum	0	1 (1.6)	0.12
Local	4 (2.7)	8 (13.1)	<0.01
Others	10 (6.7)	3 (4.9)	0.62

PNI = perineural invasion.
Data are numbers with percentages in parentheses unless otherwise indicated.



Figure 2. Disease-free survival curves according to PNI status. The prognosis of the PNI-positive group was significantly poorer than that of the PNI-negative group ($P < 0.01$). PNI = perineural invasion.

In this study, the incidence of PNI in pT3 or pT4 colorectal cancer was 26 percent. The reported incidence of PNI has differed among previous studies, and in patients with advanced cancer, the incidence has ranged between 14 and 50 percent.[7–11,14] These differences are thought to have been the result of the different definitions of PNI employed. Therefore, a clear definition of PNI is very important for clinical use, and we consider our present definition to be a candidate.

Table 3.
Five-Year Disease-Free Survival Rate According to Tumor Site and Stage

	PNI negative	PNI-positive	*P* Value
Colon			
Stage II	94 (134)	80 (20)	0.02
Stage III	75.8 (95)	52.9 (51)	0.03
Adjuvant chemotherapy +	93.3 (15)	61.5 (13)	0.04
Adjuvant chemotherapy −	72.5 (80)	50 (38)	0.01
Rectum			
Stage II	78.7 (75)	64.3 (14)	0.21
Stage III	63 (73)	38.3 (47)	<0.01
Adjuvant chemotherapy +	71.4 (14)	44.4 (9)	0.08
Adjuvant chemotherapy −	61 (59)	36.8 (38)	0.01

PNI = perineural invasion.
Data are percentages with numbers in parentheses unless otherwise indicated.

Immunohistochemical evaluation can be used to confirm the presence of PNI.[23] Use of an antibody against S-100 protein showed that the incidence of PNI was 70 percent, which was more than four times the incidence revealed by routine staining. This PNI positivity rate was very high, and patients with a poor prognosis were not selected using that method and immunohistochemistry was not always used for routine pathology because of the labor, time, and cost involved.

Venous invasion and lymphatic invasion are considered to be poor prognostic factors in patients with colorectal cancer.[18] In our study, venous invasion and lymphatic invasion were significant prognostic factors in univariate analysis but were not significant in multivariate analysis, and cancer invasion to Auerbach's plexus was selected as an indicator of poor prognosis. Our data suggest that cancer invasion to Auerbach's plexus is considered to be a more important prognostic factor than venous and lymphatic invasion.

Although many molecular markers for colorectal cancer have been studied, and some, such as p53 and DCC, have been considered to indicate prognosis, some of the evidence is conflicting,[24] and these markers are still not used in routine pathology. Moreover, these techniques are labor-intensive, time-consuming, and expensive. Because PNI can be easily detected by routine pathologic examination, it is easy to add this simple finding to pathology reports.



Figure 3. Disease-free survival curves of Stage III patients according to PNI status and cancer site. For both colon and rectal cancer, disease-free survival in the PNI-positive group was significantly poorer than that in the PNI-negative group ($P=0.03$ and $P<0.01$, respectively). PNI = perineural invasion.

Table 4.
Multivariate Analysis of the Prognostic Factors

Prognostic Factors	*P* Value	Hazards Ratio (CI)
Lymph node status (pN0/pN1, 2)	<0.0001	0.37 (0.25–0.57)
Tumor (colon/rectum)	<0.0001	0.44 (0.3–0.64)
PNI (negative/positive)	<0.0001	0.47 (0.32–0.68)
Depth of invasion (pT3/pT4)	0.0004	0.44 (0.28–0.69)

PNI = perineural invasion; CI = confidence interval.

Several reports have indicated that PNI is associated with local recurrence of rectal cancer.[6,9,10,14,25] Our study also showed that local recurrence of rectal cancer was significantly associated with invasion to Auerbach's plexus, and that such invasion was significantly associated with liver metastasis in colon cancer and with liver and lung metastasis in rectal cancer. These results suggest that cancer invasion to Auerbach's plexus is an important factor not only for local recurrence but also distant metastasis.

The PNI grading system has been used in our pathology reports. Slight invasion to Auerbach's plexus is classified as PNI1, massive invasion as PNI3, and

intermediate invasion as PNI2. However, only 20 percent of PNI cases were classified as PNI2 and 3, and there were no significant differences in outcome among these grades (data not shown). This indicates that the presence, rather than the extent, of cancer invasion to Auerbach's plexus is important for prognosis.

CONCLUSIONS

Cancer invasion to Auerbach's plexus is an important prognostic factor for colorectal cancer, and this should form the basis for defining PNI.

REFERENCES

1. Krasna MJ, Flancbaum L, Cody RP, Shneibaum S, Ben Ari G. Vascular and neural invasion in colorectal carcinoma. Incidence and prognostic significance. Cancer 1988; 61:1018–23.
2. Mulcahy HE, Toner M, Patchett SE, Daly L, O'Donoghue DP. Identifying stage B colorectal cancer patients at high risk of tumor recurrence and death. Dis Colon Rectum 1997;40:326–31.
3. Guerra A, Borda F, Javier Jimenez F, Martinez-Penuela JM, Larrinaga B. Multivariate analysis of prognostic factors in resected colorectal cancer: a new prognostic index. Eur J Gastroenterol Hepatol 1998;10:51–8.
4. Di Fabio F, Nascimbeni R, Villanacci V, *et al.* Prognostic variables for cancer-related survival in node-negative colorectal carcinomas. Dig Surg 2004;21:128–33.
5. Onate-Ocana LF, Montesdeoca R, Lopez-Graniel CM, *et al.* Identification of patients with high-risk lymph node-negative colorectal cancer and potential benefit from adjuvant chemotherapy. Jpn J Clin Oncol 2004;34:323–8.
6. Seefeld PH, Bargen JA. The spread of carcinoma of the rectum: invasion of lymphatics, veins and nerves. Ann Surg 1943;118:76–90.
7. Knudsen JB, Nilsson T, Sprechler M, Johansen A, Christensen N. Venous and nerve invasion as prognostic factors in postoperative survival of patients with resectable cancer of the rectum. Dis Colon Rectum 1983;26:613–7.
8. Bentzen SM, Balslev I, Pedersen M, *et al.* A regression analysis of prognostic factors after resection of Dukes' B and C carcinoma of the rectum and rectosigmoid. Does postoperative radiotherapy change the prognosis? Br J Cancer 1988;58:195–201.
9. Horn A, Dahl O, Morild I. Venous and neural invasion as predictors of recurrence in rectal adenocarcinoma. Dis Colon Rectum 1991;34:798–804.
10. Shirouzu K, Isomoto H, Kakegawa T. Prognostic evaluation of perineural invasion in rectal cancer. Am J Surg 1993;165:233–7.
11. Bognel C, Rekacewicz C, Mankarios H, *et al.* Prognostic value of neural invasion in rectal carcinoma: a multivariate analysis on 339 patients with curative resection. Eur J Cancer 1995;31:894–8.
12. Moreira LF, Kenmotsu M, Gochi A, Tanaka N, Orita K. Lymphovascular and neural invasion in low-lying rectal carcinoma. Cancer Detect Prev 1999;23:123–8.
13. Galindo-Gallego M, Fernandez-Acenero MJ, Sanz-Ortega J, Aljama A, Lopez-Elzaurdia C. Prognostic significance of microvascular counts in rectal carcinoma. Pathol Res Pract 2000;196:607–12.
14. Ueno H, Hase K, Mochizuki H. Criteria for extramural perineural invasion as a prognostic factor in rectal cancer. Br J Surg 2001;88:994–1000.
15. Law WL, Chu KW. Anterior resection for rectal cancer with mesorectal excision: a prospective evaluation of 622 patients. Ann Surg 2004;240:260–8.
16. Guillem JG, Chessin DB, Cohen AM, *et al.* Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg 2005;241:829–36.
17. Krebs B, Kozelj M, Kavalar R, Gajzer B, Gadzijev EM. Prognostic value of additional pathological variables for long-term survival after curative resection of rectal cancer. World J Gastroenterol 2006;12:4565–8.
18. Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 2000;88:1739–57.
19. Fujita S, Shimoda T, Yoshimura K, Yamamoto S, Akasu T, Moriya Y. Prospective evaluation of prognostic factors in patients with colorectal cancer undergoing curative resection. J Surg Oncol 2003;84:127–31.
20. Wied U, Nilsson T, Knudsen JB, Sprechler M, Johansen A. Postoperative survival of patients with potentially curable cancer of the colon. Dis Colon Rectum 1985;28:333–5.
21. Takahashi Y, Tucker SL, Kitadai Y, *et al.* Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997;132:541–6.
22. Burdy G, Panis Y, Alves A, Nemeth J, Lavergne-Slove A, Valleur P. Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence. Dis Colon Rectum 2001;44:1682–8.
23. Bellis D, Marci V, Monga G. Light microscopic and immunohistochemical evaluation of vascular and neural invasion in colorectal cancer. Pathol Res Pract 1993;189:443–7.
24. Anwar S, Frayling IM, Scott NA, Carlson GL. Systematic review of genetic influences on the prognosis of colorectal cancer. Br J Surg 2004;91:1275–91.
25. Ross A, Rusnak C, Weinerman B, *et al.* Recurrence and survival after surgical management of rectal cancer. Am J Surg 1999;177:392–5.

Original Paper

Digestive Surgery

Dig Surg 2007;24:375–381
DOI: 10.1159/000107779

Received: October 4, 2006
Accepted: April 4, 2007
Published online: August 31, 2007

Impact of Upward Lymph Node Dissection on Survival Rates in Advanced Lower Rectal Carcinoma

Keisuke Uehara Seiichiro Yamamoto Shin Fujita Takayuki Akasu
Yoshihiro Moriya

Division of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan

Key Words
Lymph node dissection · Upward lymph node dissection · Lower rectal carcinoma

Abstract
Background/Aims: This study investigated appropriate level of upward lymph node (LN) dissection in advanced lower rectal carcinoma. ***Methods:*** A total of 285 consecutive patients with stage II/III lower rectal carcinoma were analyzed. LN dissection was classified as follows: division of the root of the superior rectal artery (UD2), division of the root of the inferior mesenteric artery (UD3) and UD3 with para-aortic LN dissection (UD4). ***Results:*** LN metastases at the root of the inferior mesenteric artery were found in 4 patients. Their prognoses were worse than those of the other stage III patients ($p = 0.011$). On the other hand, LN metastases along the superior rectal artery were discovered in 14 patients, whose 5-year overall survival rate was 61.2%. By removing the LNs either UD2 or UD3/4, a similar survival rate was achieved in stage III patients with LN metastases along the superior rectal artery. ***Conclusion:*** Survival of a minority with metastatic LNs at the root of the inferior mesenteric artery was poor. Additionally, survival is no worse in patients with positive LN along the superior rectal artery as long as these positive nodes are resected by either UD2 or UD3/4. Low ligation is adequate for advanced lower rectal carcinoma.

Introduction

It is well known that lower rectal carcinoma has two routes of lymphatic spread, i.e. upward and lateral spread. There have been many reports that discuss the significance of lateral pelvic lymph node dissection for advanced lower rectal carcinoma [1–4]. However, there have not been any definitive conclusions and various opinions have been expressed around the world. On the other hand, the impact of upward lymph node dissection for sigmoid colon or upper rectal carcinoma has been discussed in several reports [5–7], and yet few studies have focused on this issue in advanced lower rectal carcinoma. Although Pezim et al. [8] reported that high ligation of the inferior mesenteric artery had no survival advantage for rectal carcinoma patients, no counterarguments have been published and it remains difficult to generalize about the impact of upward lymph node dissection. The appropriate extent of upward lymph node dissection for advanced lower rectal carcinoma remains an unsolved issue and guidelines need to be established.

This study presents a detailed estimation of how the level of upward lymph node dissection affects survival rates following curative resection in advanced lower rectal carcinoma.

KARGER

Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

0253–4886/07/0245–0375$23.50/0

Accessible online at:
www.karger.com/dsu

Seiichiro Yamamoto
Division of Colorectal Surgery, National Cancer Center Hospital
5-1-1, Tsukiji, Chuo-ku
Tokyo 104-0045 (Japan)
Tel. +81 3 3542 2511, Fax +81 3 3542 3815, E-Mail seyamamo@ncc.go.jp

Patients and Methods

Between 1990 and 2002, a series of 303 consecutive patients at the National Cancer Center Hospital, Tokyo, underwent curative surgery for stage II or III lower rectal carcinoma. Lower rectal carcinoma was defined as a tumor with a distal margin 7 cm or less from the dentate line by digital examination and/or proctoscopy. Five patients with a history of malignancy (sigmoid colon carcinoma in 3 and bladder carcinoma in 2), who previously underwent lymph node dissection along the inferior mesenteric artery or in the lateral pelvis, were excluded, because the routes of lymphatic spread seemed to be changed in these cases. Two patients with synchronous advanced rectosigmoid carcinoma were excluded. Three stage II patients and 8 stage III patients did not undergo lymph node dissection along the inferior mesenteric artery but only in the mesorectum (UD1), because of preoperative underestimation. These 11 patients were also excluded. Consequently, 285 patients were eligible for this study. The mean (SD) distance from the dentate line of the tumor was 2.4 (1.0) (range 0.0–7.0) cm. No patients received preoperative radiotherapy and/or chemotherapy. All patients were evaluated before surgery by total colonoscopy, barium enema and computed tomography. To evaluate comorbid conditions, cardiopulmonary function and renal function tests were performed. In our study, lateral pelvic lymph nodes were regarded as regional lymph nodes according to the Japanese classification of colorectal carcinoma [9], although lateral pelvic lymph node metastases are regarded as distant metastases in the TNM classification system [10]. Clinical stage II or III middle or lower rectal carcinoma, located at or below the peritoneal reflection, is an indication for lateral pelvic lymph node dissection in our hospital [2, 3]. Postoperative adjuvant chemotherapy using oral or intravenous fluoropyrimidines was administered for 6 months to 27 stage III patients. Two stage III patients received postoperative radiotherapy and another underwent concomitant chemoradiotherapy.

The incidence of upward lymph node metastases based on histopathological data from the resected specimen, recurrence sites and survival rate were retrospectively analyzed and the appropriate extent of upward lymph node dissection for advanced lower rectal carcinoma was evaluated.

Classification of the Level of Upward Lymph Node Dissection

Standard surgical procedures at our institution were previously reported in detail [11, 12]. The extent of upward lymph node dissection was classified as follows: UD1 is defined as resection of the mesorectum, UD2 as division of the root of the superior rectal artery with lymph node dissection below that level, UD3 as division of the root of the inferior mesenteric artery with lymph node dissection below that level and UD4 as UD3 with the addition of para-aortic lymph node dissection (fig. 1) [12]. The level of upward lymph node dissection was determined by preoperative and intraoperative findings. When a patient was diagnosed as stage I, UD1 to UD2 lymph node dissection was performed. UD2 to UD4 lymph node dissection was performed for patients with stage II or III tumor. UD4 was performed until the first half of the 1990s, but has not been performed thereafter because of excessive operative time, blood loss and a high incidence of postoperative sexual dysfunction, especially in males [11, 13, 14].



Fig. 1. Classification of the level of upward lymph node dissection. UD1 is defined as resection of the mesorectum; UD2 as division of the root of the superior rectal artery (SRA) and lymph node dissection below this level; UD3 as division of the root of the inferior mesenteric artery (IMA) and lymph node dissection below this level; and UD4 as UD3 with para-aortic lymph node dissection. IVC = Inferior vena cava; LCA = left colic artery.

Statistical Analysis

Survival curves were traced using the Kaplan-Meier method. The differences between curves were tested using the log-rank test. Comparisons between groups were performed using χ^2 test. $p < 0.05$ was considered significant. All statistical calculations were made using SPSS computer software (SPSS 11.0, SPSS Inc., Chicago, Ill., USA).

Results

The characteristics of 285 patients according to the UD classification are shown in table 1. There were 78 (27.4%), 133 (46.7%) and 74 (26.0%) patients who underwent UD2, UD3 and UD4, respectively. All patients were followed up until death or for at least 3 years with a mean follow-up period of 66 months. The rate of sphincter-pre-

Table 1. Patient characteristics according to the UD classification

	Total (n = 285)	UD2 (n = 78)	UD3 (n = 133)	UD4 (n = 74)
Age, years (mean)	58.2	58.1	58.2	58.4
Sex ratio (male:female)	191:94	53:25	90:43	48:26
Follow-up period (mean)	66	59	57	88[a, c]
Surgical procedure				
Sphincter-preserving surgery	143 (50.2)	53 (67.9)	64 (48.1)	26 (35.1)[a, b]
Non-sphincter-preserving surgery	142 (49.8)	25 (23.1)	69 (51.9)	48 (64.9)
Lateral LNs dissection				
No	68 (23.9)	32 (41.0)	31 (23.3)	5 (6.8)[d]
Yes	217 (76.1)	46 (59.0)	102 (76.7)	69 (93.2)
Evaluated LN, n (mean)	42	31	39	57[d]
Metastatic LN, n (mean)	3	2	3	3
TNM classification				
Stage II	94 (33.0)	29 (37.2)	38 (28.6)	27 (36.5)
Stage III	191 (67.0)	49 (62.8)	95 (71.4)	47 (63.5)

Values in parentheses are percentages.
[a] $p < 0.05$ UD2 vs. UD3, [b] $p < 0.05$ UD2 vs. UD4, [c] $p < 0.05$ UD3 vs. UD4, [d] $p < 0.05$ between each UD classification.

serving surgery was higher in UD2 patients than in those who underwent UD3 or UD4. The rate of undergoing lateral lymph node dissection and the number of evaluated lymph nodes increased significantly with the extension of upward lymph node dissection. However, there were no significant differences in the number of metastatic lymph nodes and the ratio of stage II to III among UD classifications.

In each TNM stage, the overall survival curves in relation to the extent of upward lymph node dissection were evaluated and there were no significant differences according to the extent of upward lymph node dissection (fig. 2). Recurrence sites after curative resection are demonstrated in table 2. In both groups with or without lymph node dissection at the root of the inferior mesenteric artery, the lung was the most common site of recurrence followed by the liver. Recurrence sites did not significantly differ between the groups, including para-aortic or mediastinal lymph node metastases.

Table 3 summarizes the characteristics and outcomes of 4 patients with lymph node metastases at the root of the inferior mesenteric artery. They accounted for 1.9% of the 207 patients who underwent UD3 or UD4. Recurrences developed in all cases and their prognoses were significantly worse than those of the other stage III patients who underwent UD3 or UD4 ($p = 0.011$) (fig. 3). None of 4 patients survived for 5 years.

Table 2. Recurrent sites after curative resection

Recurrent site	UD2 (n = 78)	UD3/UD4 (n = 207)	p value
Lung	16 (20.5)	36 (17.4)	0.543
Liver	6 (7.7)	19 (9.2)	0.692
Pelvic cavity	7 (9.0)	15 (7.2)	0.626
Para-aortic or mediastinal LNs	3 (3.8)	4 (1.9)	0.352

Values in parentheses are percentages.

On the other hand, lymph node metastases along the superior rectal artery were discovered in 14 patients, excluding 3 patients with metastatic lymph nodes at the root of the inferior mesenteric artery, and table 4 shows their characteristics. They accounted for 4.9% of all patients. Ten patients developed recurrence and the lung was the most common site (6 patients), followed by the liver (2 patients). The 5-year overall survival rate was 61.2% in this group and there were no significant differences in overall survival among the patients with and without lymph node metastases along the superior rectal artery ($p = 0.338$) (fig. 4a). In addition, there were no significant differences in survival of the patients with lymph node metastases along the superior rectal artery according to the extension of upward lymph node dissection performed (UD2 or UD3/4) ($p = 0.642$) (fig. 4b).



Fig. 2. Overall survival curves in relation to the extent of upward lymph node dissection at each stage: (**a**) stage II and (**b**) stage III. There were no significant differences in each stage.



Fig. 3. Overall survival curves for the stage III patients with or without metastatic lymph nodes at the root of the inferior mesenteric artery (IMA). The former was significantly worse than the latter ($p = 0.011$).

Table 3. Characteristics of the patients with metastatic LNs at the root of the inferior mesenteric artery

Age	Sex	UD	Histology	pT	Metastatic LNs, n	Recurrent site	Disease-free time, months	Outcome months
33	F	3	well-differentiated adenocarcinoma	pT3	3	lung, bone	25	died (54)
64	F	3	moderately differentiated adeno-carcinoma	pT3	4	lung	22	alive with recurrent tumor (39)
51	M	3	poorly differentiated adenocarcinoma	pT3	25	pelvic cavity	11	died (19)
57	M	3	poorly differentiated adenocarcinoma	pT3	16	pelvic cavity, peritonium	4	died (6)

Discussion

Surgical decisions regarding upward lymph node dissection for advanced lower rectal carcinoma remain controversial. In our study, patients with metastatic lymph nodes at the root of the inferior mesenteric artery comprised a small minority (4 patients, 1.9%) and their prognoses were very poor. Their prognoses seemed to be almost equal to those of patients who underwent UD4 dissection and were pathologically proven to have metastatic para-aortic lymph node, although such patients are classified as stage IV in TNM classification and were excluded from this study. Furthermore, we could not demonstrate an effect of prophylactic lymph node dissection at the root of the inferior mesenteric artery in patients with any stage of disease. Moreover, lymph node dissection without the root of the inferior mesenteric artery did not result in increased para-aortic or mediastinal lymph node metastases, which we had thought might be caused by failing to perform lymph node dissection. We conclude that lymph node dissection at the root of the inferior mesenteric artery does not provide any survival advantage for patients with advanced lower rectal carcinoma and metastatic lymph nodes at this level have systematic disease.

Likewise, there were also a small number of patients with metastatic lymph nodes along the superior rectal artery (14 patients, 4.9%) and the positive rate was far below the rate of lateral lymph nodes (55 of 217 patients who underwent lateral lymph node dissection, 25.3%) in this series. However, the 5-year overall survival rate in this group was 61.2% and there were no significant differences among stage III patients with and without lymph node metastases along the superior rectal artery. In addition, survival is no worse in patients with positive lymph node along the superior rectal artery as long as these positive nodes are resected by either UD2 or UD3/4. We conclude that UD2 lymph node dissection is adequate even for stage III patients with lymph node metastases along the superior rectal artery.

Table 4. Characteristics of the patients with metastatic LNs along the SRA (exception for three with metastatic LNs at the root of the IMA)

Patients		14
Age, years (mean)		58.8
Sex ratio (male:female)		12:2
Upward LNs dissection	UD2	4
	UD3	6
	UD4	4
Lateral LNs dissection	no	5
	unilateral pelvic	2
	bilateral pelvic	7
pT category in TNM classification	pT1	2
	pT2	2
	pT3	7
	pT4	3
pN category in TNM classification	pN1	7
	pN2	7
Recurrence	yes	10
	no	4

SRA = Superior rectal artery; IMA = inferior mesenteric artery.

There are some problems with the existing classifications of rectal carcinoma. TNM classification considers lymph nodes at the root of the inferior mesenteric artery as regional lymph nodes for colorectal carcinoma without regard to the location of the tumors, as well as lymph nodes along the superior rectal artery [10]. Under this classification, patients with metastatic regional lymph nodes are regarded as stage III and are subcategorized into three groups by the depth of tumor invasion and number of metastatic lymph nodes, not by the location of metastatic lymph nodes. The problem with this classification is that we cannot distinguish whether stage III patients have lymph node metastases at the root of the inferior mesenteric artery.



Fig. 4. a Overall survival curves for stage III. patients with or without metastatic lymph nodes along the superior rectal artery, excluding 4 patients with lymph node metastases at the root of the inferior mesenteric artery. There were no significant differences in overall survival between both groups ($p = 0.338$). **b** Overall survival curves in relation to the extent of upward lymph node dissection for stage III patients with metastatic lymph nodes along the superior rectal artery, excluding 3 patients with lymph node metastases at the root of the inferior mesenteric artery. There were no significant differences in survival of the patients with lymph node metastases along the superior rectal artery according to the extension of upward lymph node dissection performed (UD2 or UD3/4) ($p = 0.642$).

In comparison, the Japanese classification of colorectal carcinoma [9] treats regional lymph nodes in rectal carcinoma as follows: pararectal lymph nodes are defined as group 1, lymph nodes along the superior rectal artery as intermediate lymph nodes (group 2) and lymph nodes at the root of the inferior mesenteric artery as the main lymph nodes (group 3). However, this classification defines patients with metastatic lymph nodes in group 2 and/or group 3 as same stage (stage IIIb). Based on the results of this study, these criteria should be reevaluated.

In recent years, sphincter-preserving surgery has been increasingly adopted in patients with lower rectal carcinoma [15, 16]. The most important postoperative complication in this procedure is anastomotic leakage. To avoid this complication, all colorectal surgeons pay attention to blood flow in the remnant colon, together with the tension of the anastomosis. Therefore, Western surgeons perform mobilization of the splenic flexure for most patients [17], but the position of the splenic flexure in Japanese is usually very deep in the left upper subphrenic area and it is sometimes rather difficult to mobilize the left side colon. However, Japanese patients usually have a long sigmoid colon, and if the surgeon preserves 1 or 2 arcades of marginal vessels of the sigmoid colon by dividing the sigmoid artery between the superior rectal artery and these marginal vessels, mobilization of the splenic flexure becomes unnecessary. In this situation, arterial blood flow is not being compensated. Preservation of the blood flow of the left colic artery is one solution to this problem,

because the appropriate extent of upward lymph node dissection for lower rectal carcinoma is considered to be UD2. When the length of the vascular pedicle for lower anastomosis is short, we can cut the periphery of the left colic artery. Some surgeons choose left colic artery-preserving lymph node dissection at the root of the inferior mesenteric artery, but this increases the risk of damaging the lumbar splanchnic nerve.

Another problem encountered with lymph node dissection for lower rectal surgery is lateral lymph node dissection. Some reports mainly from Japan have supported the effectiveness of lateral pelvic lymph node dissection, and it is well established as the standard procedure in leading hospitals in Japan. However, in Western countries, the survival benefits of lateral pelvic lymph node dissection are regarded as doubtful. Instead, preoperative chemoradiotherapy is widely performed [18, 19]. To resolve this disparity, a multicentric randomized clinical trial that compares lateral pelvic lymph node dissection with autonomic nerve preservation to total mesenteric excision (JCOG-0212) is underway in Japan and data regarding this issue will become available in the near future [20].

In conclusion, survival of a minority with metastatic lymph nodes at the root of the inferior mesenteric artery was very poor. In addition, survival is no worse in patients with positive lymph node along the superior rectal artery as long as these positive nodes are resected by either UD2 or UD3/4. Surgeons should take these data into consideration and recognize that low ligation is adequate for advanced lower rectal carcinoma.

References

1 Moriya Y, Sugihara K, Akasu T, Fujita S: Nerve-sparing surgery with lateral node dissection for advanced lower rectal cancer. Eur J Cancer 1995;31A:1229–1232.

2 Moriya Y, Sugihara K, Akasu T, Fujita S: Importance of extended lymphadenectomy with lateral node dissection for advanced lower rectal cancer. World J Surg 1997;21:728–732.

3 Fujita S, Yamamoto S, Akasu T, Moriya Y: Lateral pelvic lymph node dissection for advanced lower rectal cancer. Br J Surg 2003;90:1580–1585.

4 Ueno M, Oya M, Azekura K, Yamaguchi T, Muto T: Incidence and prognostic significance of lateral lymph node metastasis in patients with advanced low rectal cancer. Br J Surg 2005;92:756–763.

5 Shida H, Ban K, Matsumoto M, Masuda K, Imanari T, Machida T, Yamamoto T: Prognostic significance of location of lymph node metastases in colorectal cancer. Dis Colon Rectum 1992;35:1046–1050.

6 Surtees P, Ritchie JK, Phillips RK: High versus low ligation of the inferior mesenteric artery in rectal cancer. Br J Surg 1990;77:618–621.

7 Slanetz CA Jr, Grimson R: Effect of high and intermediate ligation on survival and recurrence rates following curative resection of colorectal cancer. Dis Colon Rectum 1997;40:1205–1218.

8 Pezim ME, Nicholls RJ: Survival after high or low ligation of the inferior mesenteric artery during curative surgery for rectal cancer. Ann Surg 1984;200:729–733.

9 Japanese Society for Cancer of the Colon and Rectum: Japanese Classification of Colorectal Carcinoma, ed 1. Tokyo, Kanehara, 1997.

10 International Union against Cancer: TNM classification of malignant tumours, ed 6. New York, Wiley-Liss, 2002.

11 Moriya Y: Pelvic node dissection with autonomic nerve sparing for invasive lower rectal cancer: Japanese experience; in Wanebo HJ (ed): Colorectal Cancer. St. Louis, Mosby, 1993, pp 274–289.

12 Akasu T, Moriya Y: Abdominopelvic lymphadenectomy with autonomic nerve preservation for carcinoma of the rectum: Japanese experience; in Wanebo HJ (ed): Surgery for Gastrointestinal Cancer: A Multidisciplinary Approach. Philadelphia, Lippincott-Raven, 1997, pp 667–680.

13 Maas CP, Moriya Y, Steup WH, Kiebert GM, Kranenbarg WM, van de Velde CJ: Radical and nerve-preserving surgery for rectal cancer in The Netherlands: a prospective study on morbidity and functional outcome. Br J Surg 1998;85:92–97.

14 Sugihara K, Moriya Y, Akasu T, Fujita S: Pelvic autonomic nerve preservation for patients with rectal carcinoma: oncologic and functional outcome. Cancer 1996;78:1871–1880.

15 Schiessel R, Novi G, Holzer B, Rosen HR, Renner K, Holbling N, Feil W, Urban M: Technique and long-term results of intersphincteric resection for low rectal cancer. Dis Colon Rectum 2005;48:1858–1867.

16 Rullier E, Laurent C, Bretagnol F, Rullier A, Vendrely V, Zerbib F: Sphincter-saving resection for all rectal carcinomas: the end of the 2-cm distal rule. Ann Surg 2005;241:465–469.

17 Milson JW, Stolfi VM: Low rectal and midrectal cancers; in Wanebo HJ (ed): Colorectal Cancer. St. Louis, Mosby, 1993, pp 214–241.

18 Rullier E, Goffre B, Bonnel C, Zerbib F, Caudry M, Saric J: Preoperative radiochemotherapy and sphincter-saving resection for T3 carcinomas of the lower third of the rectum. Ann Surg 2001;234:633–640.

19 Schaffer M, Thoma M, Wilkowski R, Schaffer P, Duhmke E: Radio-chemotherapy as a preoperative treatment for advanced rectal cancer: evaluation of down-staging and morbidity. Onkologie 2002;25:352–356.

20 http://clinicaltrials.gov/ct/gui/show/NCT00190541 [ClinicalTrials.gov web site]. Accessed October 4, 2006.

Incidence and Patterns of Recurrence after Intersphincteric Resection for Very Low Rectal Adenocarcinoma

Takayuki Akasu, MD, Masashi Takawa, MD, Seiichiro Yamamoto, MD, Shin Fujita, MD, Yoshihiro Moriya, MD

BACKGROUND: The aim of this study was to evaluate the incidence and patterns of recurrence, or oncologic safety, after intersphincteric resection (ISR) without radiotherapy for very low rectal adenocarcinoma.

STUDY DESIGN: One hundred eight consecutive patients with T1–T3 rectal cancers located 1 to 5 cm (median 3 cm) from the anal verge underwent ISR. A retrospective analysis of prospectively recorded data from the 106 patients not receiving radiotherapy was performed.

RESULTS: There were 23 T1, 40 T2, and 43 T3 tumors. Morbidity and mortality rates were 33% and 1%, respectively. The 3-year rates of overall local recurrence and survival were 5.7% and 95%, respectively. The 3-year cumulative local recurrence rate was 0% for the patients with T1–T2 tumors as compared with 15% for those with T3 tumors ($p = 0.0012$). In T3 tumors, the 2-year local recurrence rate was 5% for patients with negative surgical margins as compared with 33% for those with positive margins ($p = 0.0001$). The incidences of distant recurrence for stages I, II, III, and IV disease were 4%, 5%, 18%, and 33%, respectively.

CONCLUSIONS: ISR does not increase local or distant recurrences. For T1–T2 tumors, meticulous dissection and irrigation after closure of the distal stump allows local control without radiotherapy. With T3 tumors, preoperative therapy should be considered if resection margins are estimated to be insufficient. (J Am Coll Surg 2007;205:642–647. © 2007 by the American College of Surgeons)

Standard surgical treatment for massively invading rectal adenocarcinoma located within 5 cm from the anal verge is abdominoperineal resection.[1] This is because the length of the anal canal is 3 to 5 cm,[2] and a distal margin of at least 1 cm, but preferably 2 cm, should be taken to ensure local control.[1,3,4]

To avoid permanent colostomy for such patients, intersphincteric resection (ISR) was devised in the 1980s, and a modern concept of ISR was established in the 1990s.[4] ISR is now defined as a procedure obtaining sufficient margins by removing part or all of the internal sphincter and restoring bowel continuity for patients with rectal cancers involving or neighboring the anal canal. With meticulous performance of this operation, satisfactory early results on defecatory functions and oncologic outcomes were reported.[4,5]

But with ISR, there is a potential risk of increasing recurrence, especially local recurrence, because preservation of the anal canal, external sphincter, and levator ani muscles for such low tumors may compromise distal or circumferential resection margins. There have been only limited studies on longterm oncologic outcomes after ISR.[6-8] The purpose of this study was to review our results of ISR for rectal adenocarcinoma within 5 cm from the anal verge and to evaluate the incidence and patterns of recurrence, as parameters of oncologic safety, after ISR without radiotherapy.

METHODS

Between October 1993 and November 2005, 108 patients with massively invasive rectal adenocarcinomas located within 5 cm from the anal verge underwent ISR at the National Cancer Center Hospital, Tokyo. During the same

Competing Interests Declared: None.

This study was supported in part by a grant-in-aid for Clinical Research for Evidence Based Medicine; a grant-in-aid for Cancer Research from the Ministry of Health, Labor and Welfare; and a grant from the Foundation for Promotion of Cancer Research in Japan.

Received April 4, 2007; Revised May 23, 2007; Accepted May 30, 2007.

From the Colorectal Surgery Division, National Cancer Center Hospital, Tokyo, Japan.

Correspondence address: Takayuki Akasu, MD, Colorectal Surgery Division, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

ISSN 1072-7515/07/$32.00
doi:10.1016/j.jamcollsurg.2007.05.036

period, 201 patients underwent abdominoperineal resection for rectal cancer located within 5 cm from the anal verge. The proportions of ISR were 18% (28 of 157) until 2001 and 52% (78 of 150) thereafter. Selection criteria for ISR were sufficient medical fitness; normal sphincter function; distance between the tumor and the anorectal junction (upper edge of the surgical anal canal) of less than 2 cm; no involvement of the external sphincter; and no signs of disseminated disease. Patients were routinely assessed with chest and abdominal CT, digital anorectal examination, and radiologic studies, including endorectal ultrasonography[9] until 1997, thin-section helical CT until 2000, and thin-section MRI with a phased-array coil[10] from 2001 on. Written informed consent was obtained from all patients.

Retrospective analysis of clinicopathologic data from the prospective database and medical records of the 106 consecutive patients who did not receive adjuvant radiotherapy was conducted. Data from the remaining two patients given radiotherapy were excluded from this analysis. There were 83 men and 23 women, with a median age of 55 years (range 26 to 75 years). The median distance from the tumor to the anal verge was 3 cm (range 1 to 5 cm).

Treatment

Ninety patients underwent partial ISR and 16 had complete ISR. A small part of the external sphincter was resected in six patients to obtain sufficient surgical margins. Extent of lymph node dissection included total mesorectal excision in 63 patients and total mesorectal excision plus extended lateral pelvic lymph node dissection in 43. Combined resection was performed for six patients (vagina, two; uterus, one; pelvic plexus, two; internal iliac vessels, one).

ISR was carried out through a laparotomy in 101 patients and laparoscopically in 5. A J pouch was made in 24 patients, a transverse coloplasty pouch in 35, and a straight anastomosis in 47, according to the operator's preference. Ninety-five patients had covering ileostomy, two had colostomy, and nine had no stoma. Two patients with a solitary liver metastasis and one with a solitary lung metastasis underwent complete resection of their metastases. Postoperatively, 19 patients received adjuvant chemotherapy with a 5-fluorouracil–based regimen.

Surgical procedure

The surgical procedures were basically similar to those originally described by Schiessel and colleagues[4,7] The patient was placed in a supine position with flexed and abducted thighs. The sigmoid colon and rectum were mobilized down to the levator ani. The intersphincteric plane, between the puborectalis and the external sphincter, and the internal sphincter were dissected cautiously as far as possible under direct vision, using electrocautery. If the lower edge of the tumor was reached, a vertical stapler was applied just below the tumor to close the rectum or anal canal, and then the anal canal was washed with povidone iodine followed by saline.

A Gelpi retractor or a self-holding retractor (Lone Star Retractor; Lone Star Medical Products Inc) was applied to the anal canal, the internal sphincter was circumferentially incised, and the intersphincteric plane was dissected with electrocautery under direct vision. A resection margin of at least 1 cm was always attempted. If the rectum was not closed in the abdominal phase, it was closed using sutures after per-anal dissection. After removal of the rectum, the pelvic cavity and anal canal were irrigated with povidone iodine and then with saline. Then a coloanal anastomosis was made using vertical mattress sutures.

Followup

All patients were followed for a median of 3.5 years (range 0.9 to 11.7 years) for those who remained alive, and 83 patients (78%) could be followed for more than 2 years. Patients with stage I tumors were examined with chest and abdominopelvic CT and carcinoembryonic antigen measurement every year for at least 5 years. Patients with stage II tumors were examined every 6 months for 2 years, then yearly for at least 3 years. Patients with stage III tumors were examined every 4 months for 2 years, then every 6 months for at least 3 years.

Statistical analysis

The starting point for survival and recurrence-free intervals was the day of operation, and data on patients who were alive or free of recurrence were censored at the last followup. Overall survival was defined as the time from ISR until death from any cause. Local recurrence was defined as that confined to the pelvis and distant recurrence as present outside of the pelvis.

Survival curves were estimated by the Kaplan-Meier method, and differences in survival were evaluated with the log-rank test. The significance of differences in proportions was calculated with the chi-square test. All statistical analyses were performed using SPSS for Windows, version 11.0J (SPSS-Japan Inc). All p values were two sided, and a p value of less than 0.05 was considered statistically significant.

RESULTS

Pathologic findings

Histologic diagnoses were well, moderate, and poorly differentiated adenocarcinomas in 52, 46, and 5 patients, respectively, and mucinous carcinoma in 3. The median tu-



No. at risk 106 100 82 62 35 19 11

Figure 1. Overall survival among 106 patients undergoing intersphincteric resection.



No. at risk						
Overall	106	94	75	56	30	16
Distant	106	96	75	57	32	18
Local	106	97	81	60	33	17

Figure 2. Rates of overall recurrence, distant recurrence, and local recurrence among 106 patients undergoing intersphincteric resection.

mor size was 3.7 cm (range 1 to 12 cm). Resection margins were microscopically negative in 103 patients and positive in 3. One patient had both circumferential and distal positive margins and the other two had a circumferential positive margin. Excluding these 3 patients, the median distal margin was 1.2 cm (range 0.3 to 4 cm). Histologic depth of invasion included T1 in 23 patients, T2 in 40, and T3 in 43. All T1 tumors had massive invasion, lymphatic invasion, venous invasion, or poor differentiation. Lymph node statuses were N0 in 66, N1 in 25, and N2 in 15. Seven patients (7%) had lateral pelvic lymph node metastasis and 3 had distant metastases (liver, 2; lung, 1). Histologic staging included stage I in 45 patients, II in 20, III in 38, and IV in 3.

Morbidity and mortality

Of 35 patients (33%) who suffered from complications, 26 were treated conservatively and 9 had operations. Of 13 patients (12%) with anastomotic leakage, 6 underwent operations. The incidence of anastomotic leakage in the patients without covering stoma was not higher than that in the patients with covering stoma (11% [1 of 9] versus 12% [12 of 97], respectively). Other complications included wound infection, bowel obstruction, urinary tract infection, anal pain, anastomotic stenosis, anal prolapse, peristomal hernia, thrombocytopenia, and cholecystitis. One patient who had anastomotic leakage and sepsis died on the third postoperative day (mortality = 1%). Seven patients had a permanent stoma because of complications (six patients) or local recurrence (one patient).

Survival

At the last followup in December 2006, 100 patients were alive and 6 were dead. Causes of death included rectal cancer (two patients), gastric cancer (one), pancreatic cancer (one), anastomotic leakage (one), and cerebral contusion (one). The estimated overall 3- and 5-year survival rates were 95% and 91%, respectively, including 1 hospital death (Fig. 1).

Incidence and patterns of recurrence

A total of 16 patients (15%) developed recurrence. Estimated 3- and 5-year cumulative rates for overall recurrence were 15% and 18%, respectively (Fig. 2). Sites of the first recurrence included the pelvis in five patients, pelvis and lung in one, inguinal lymph nodes in two, lung in four, lung and liver in one, and liver in three. The incidences of overall recurrence for stages I, II, III, and IV disease were 4%, 25%, 21%, and 33%, respectively.

Estimated 3- and 5-year cumulative rates for distant recurrence, found in 11 patients (11%), were 11% and 12%, respectively (Fig. 2). The incidences of distant recurrence for stages I, II, III, and IV disease were 4%, 5%, 18%, and 33%, respectively.

In total, 6 patients (5.7%) developed local recurrence, with estimated 3- and 5-year cumulative recurrence rates of 5.7% and 7.3%, respectively (Fig. 2). Detailed sites of local failure included the circumferential resection margin in two patients, internal iliac or obturator nodes in three, and sacrum in one. The incidences of local failure for stages I, II, III, and IV disease were 0%, 20%, 5%, and 0%, and those for pathologic T1, T2, and T3 tumors were 0%, 0%, and 14%, respectively.

Estimated cumulative rate of local recurrence with T1–2 tumors was significantly less than that with T3 tumors



No. at risk

T1–T2	63	60	50	41	20	9
T3	43	36	30	18	12	7

Figure 3. Rates of local recurrence among 106 patients undergoing intersphincteric resection, according to the pathologic depth of transmural invasion (T stage).

(p = 0.0012; 3-year rates of local recurrence, 0% versus 15%, respectively; Fig. 3). All 6 patients developing local failure had T3 tumors. Of the 100 patients without local failure, 37 had T3 tumors, and 63 had T1–2 tumors. Sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy rate for T3 tumors in prediction of local failure were 100% (6 of 6), 63% (63 of 100), 14% (6 of 43), 100% (63 of 63), and 65% (69 of 106), respectively.

In T3 tumors, the estimated cumulative rate of local recurrence for patients with negative surgical margins was significantly less than that with positive margins (p = 0.0001; 2-year rates of local recurrence, 5% versus 33%, respectively). Of the six patients developing local failure, two had positive margins, but the other four had negative margins. Of the 37 patients without local failure, 36 had negative margins, and 1 had a positive margin. Sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy rate for the positive margin in prediction of local failure were 33% (2 of 6), 97% (36 of 37), 67% (2 of 3), 90% (36 of 40), and 88% (38 of 43), respectively.

Other evaluated factors, including age, gender, tumor size, pathologic TNM stage, pathologic N stage, histologic grade, distance between the tumor and anal verge, extended lateral lymph node dissection, and adjuvant chemotherapy, had no association with local recurrence.

One patient with local recurrence at the circumferential resection margin could undergo curative abdominoperineal resection, but the other five received chemoradiotherapy (three) or chemotherapy (two) alone.

DISCUSSION

This study confirmed the longterm oncologic safety of ISR for rectal adenocarcinoma located within 5 cm from the anal verge, in addition to acceptable morbidity and mortality. In this study, local recurrence and 5-year overall survival rates after ISR were 5.7% and 91%, respectively. In a large series with 117 patients, Schiessel and associates[7] reported a similar favorable local failure rate of 5.3%. There were no substantial differences in oncologic outcomes between the two studies; because our surgical procedures are based on theirs, the stage distributions were almost the same, and radiotherapy was not used in either study. In another large series with 92 patients, Rullier and coworkers[8] reported a better local recurrence rate (2%) and a slightly worse distant recurrence rate (19%), with a 5-year overall survival of 81%. These differences were attributable to the background of their patients, 85% of whom had T3 or T4 tumors and 88% of whom received preoperative radiotherapy. Considering duration of followup and prevalence of site and stage, these local recurrence rates after ISR compared favorably with the 6% to 9% reported in population-based data for anterior resection or abdominoperineal resection with total mesorectal excision.[11-13]

This study showed that invasion through the muscularis propria (T3) and positive microscopic resection margin were significantly associated with local recurrence after ISR. Although data were not shown, Schiessel and colleagues[7] reported that only Dukes stage and T stage had an impact on local failure. Paty and associates[14] analyzed data of 134 patients with rectal cancer located 2 to 11 cm (median 6.5 cm) from the anal verge, undergoing not only ISR, but also low anterior resection or coloanal anastomosis; they found that mesenteric implants, positive microscopic resection margin, T3 tumor, perineural invasion, blood vessel invasion, and poorly differentiated histology were significantly associated with pelvic recurrence in a univariate analysis. Among these factors, only T3 and positive resection margin were reproducible, so these 2 can currently serve as indicators of high risk for local failure. In this study, positive margins had better positive predictive value and overall accuracy rate than T3.

Our study clearly showed that there was no local recurrence after ISR for T1 and T2 tumors, despite the absence of adjuvant radiotherapy. So far, there have been few studies mentioning oncologic safety of ISR without radiotherapy for such tumors.[4,7] Although longterm preoperative radiotherapy is known to reduce tumor volume and change protruding tumors into ulcerative scars, facilitating operations and decreasing tumor spillage,[15] radiotherapy, in both short and long courses, has the potential to cause damage to anorectal[16,17] and sexual[18,19] functions. So, identification of

a subset of patients for whom radiotherapy is not necessary is valuable.

To select patients with T1 or T2 tumors, both transrectal ultrasonography and high-resolution MRI are sufficiently accurate, with overall accuracy rates of around 85%.[9,10] Although the frequency of overstaging of T2 tumors may be a little high with both examinations,[9] this should not increase the risk of local recurrence, because overstaging generally leads to overtreatment, rather than undertreatment.

But caution is necessary to interpret these results because in our series, total mesorectal excision with meticulous pelvic and per-anal dissection was performed, and closure of the distal stump and irrigation of raw surfaces of the pelvic cavity and anal canal were carried out for all patients. Without such procedures, favorable outcomes may not be expected.

On the other hand, local treatment has been regarded recently as an alternative option for T1 and T2 tumors, with the advantages of sphincter preservation and minimal morbidity. According to a current massive literature review,[20] low-risk T1 tumor with invasion confined to the superficial submucosa, well to moderate differentiation, and lack of lymphatic and venous invasion make a patient suitable for local excision alone; high-risk T1 or T2 tumors require radical operations or adjuvant treatment. Although the recent integration of potent chemotherapeutic agents into chemoradiotherapy has been steadily improving efficacy, the role of local excision with chemoradiotherapy in curative treatment of high-risk T1 and T2 tumors still remains to be clarified.

For T3 tumors, our local recurrence rate of 14% without radiotherapy is much higher than the 2% reported with radiotherapy,[8] so adjuvant therapy should be considered for T3 tumors, as Rullier and coauthors[8] recommended. But because 86% of our patients with T3 tumors can achieve local control without radiotherapy, it should be given only to high-risk patients, considering its toxicity to anal and sexual functions.

This study showed microscopic involvement of the circumferential resection margin to be significantly associated with local recurrence, in line with results of other studies.[13] In addition, tumor presence within 1 mm of the circumferential resection margin is reported to be a major significant risk factor for local recurrence.[13] Because preoperative radiotherapy can increase the margin,[15] this should be applied for patients with predicted insufficient margins. High-resolution MRI is useful for selecting such patients, predicting a clear circumferential resection margin with a specificity of 92% in a large prospective study of 408 patients.[21]

Although a positive distal margin caused local failure in only one of our patients, the distal margin has long been reported to be a significant risk factor of local failure.[22] MRI is useful for predicting distal margin and assigning preoperative therapy to high-risk patients. Urban and colleagues[23] used double-contrast, material-enhanced MRI with a flexible surface coil for 61 patients with rectal cancer and reported a specificity of 98% and a sensitivity of 100% in assessment of anal sphincteric infiltration.

But distal intramural spread that is microscopic invasion beyond the macroscopic tumor edge has been reported to occur in 4% to 24% of patients undergoing curative operations and to reach nearly 2 cm.[24] Although distal intramural spread has been suggested to be associated with lymph node involvement, transmural invasion depth, annularity, gross tumor appearance, and unfavorable histology,[24] clear prediction criteria have yet to be established and these warrant further investigation.

It is controversial whether lateral pelvic lymph node metastasis has a significant role in local recurrence. In our study, three of six local failures appeared to be caused by lateral node metastasis. But analyses of radiologic findings by Syk and associates[25] revealed that only 2 of 33 local failures originated from lateral node metastases among 880 rectal cancer patients undergoing total mesorectal excision. The incidence of lateral node metastasis was 7% in this study and was estimated to be between 6.5% and 9.4% in a large series with 1,977 rectal cancer patients,[26] suggesting a certain influence on local failure. So, the real incidence of lateral node metastasis and its role in determining prognosis should be investigated further in a prospective fashion.

The 3-year rate for distant recurrence in our study was 11%, and this compared favorably with the 2-year distant recurrence rate of 14% in the Total Mesorectal Excision (TME) project of the Stockholm Colorectal Cancer Study with 447 patients.[11] The Stockholm study contained slightly more advanced but more cephalad tumors than our study did. Considering this, ISR seems not to increase distant recurrence. But caution is necessary so as not to overlook inguinal lymph node recurrence. It is very rare with usual sphincter-preserving operations but can occur in patients undergoing ISR.

We concluded that ISR, in general, does not increase local or distant recurrences. With T1 and T2 tumors, if meticulous dissection and irrigation after closure of the distal stump are performed, local control is assured and radiotherapy is not necessary. For T3 tumors, if resection margins are estimated to be insufficient, preoperative therapy should be considered to reduce the risk of local failure.

Author Contributions

Study conception and design: Akasu
Acquisition of data: Akasu, Takawa, Yamamoto, Fujita, Moriya
Analysis and interpretation of data: Akasu
Drafting of manuscript: Akasu
Critical revision: Takawa, Yamamoto, Fujita, Moriya

REFERENCES

1. Nicholls RJ, Hall C. Treatment of non-disseminated cancer of the lower rectum. Br J Surg 1996;83:15–18.
2. Nivatvongs S, Stern HS, Fryd DS. The length of the anal canal. Dis Colon Rectum 1981;24:600–601.
3. Vernava AM III, Moran M, Rothenberger DA, Wong WD. A prospective evaluation of distal margins in carcinoma of the rectum. Surg Gynecol Obstet 1992;175:333–336.
4. Schiessel R, Karner-Hanusch J, Herbst F, et al. Intersphincteric resection for low rectal tumors. Br J Surg 1994;81:1376–1378.
5. Kusunoki M, Yanagi H, Shoji Y, et al. Anoabdominal rectal resection and colonic J pouch-anal anastomosis: 10 years' experience. Br J Surg 1997;84:1277–1280.
6. Gamagami RA, Liagre A, Chiotasso P, et al. Coloanal anastomosis for distal third rectal cancer: prospective study of oncologic results. Dis Colon Rectum 1999;42:1272–1275.
7. Schiessel R, Novi G, Holzer B, et al. Technique and long-term results of intersphincteric resection for low rectal cancer. Dis Colon Rectum 2005;48:1858–1865.
8. Rullier E, Laurent C, Bretagnol F, et al. Sphincter-saving resection for all rectal carcinomas: the end of the 2-cm distal rule. Ann Surg 2005;241:465–469.
9. Akasu T, Kondo H, Moriya Y, et al. Endorectal ultrasonography and treatment of early stage rectal cancer. World J Surg 2000; 24:1061–1068.
10. Akasu T, Iinuma G, Fujita T, et al. Thin-section MR imaging with a phased-array coil for preoperative evaluation of pelvic anatomy and tumor extent in patients with rectal cancer. AJR Am J Roentgenol 2005;184:531–538.
11. Martling AL, Holm T, Rutqvist LE, et al. Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet 2000;356:93–96.
12. Kapiteijn E, Putter H, van de Velde CJ, Cooperative investigators of the Dutch ColoRectal Cancer Group. Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands. Br J Surg 2002;89:1142–1149.
13. Wibe A, Rendedal PR, Svensson E, et al. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg 2002;89:327–334.
14. Paty PB, Enker WE, Cohen AM, Lauwers GY. Treatment of rectal cancer by low anterior resection with coloanal anastomosis. Ann Surg 1994;219:365–373.
15. Rullier E, Goffre B, Bonnel C, et al. Preoperative radiochemotherapy and sphincter-saving resection for T3 carcinomas of the lower third of the rectum. Ann Surg 2001;234:633–640.
16. Pollack J, Holm T, Cedermark B, et al. Long-term effect of preoperative radiation therapy on anorectal function. Dis Colon Rectum 2006;49:345–352.
17. Peeters KC, van de Velde CJ, Leer JW, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch Colorectal Cancer Group Study. J Clin Oncol 2005;23:6199–6206.
18. Marijnen CA, van de Velde CJ, Putter H, et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 2005;23:1847–1858.
19. Heriot AG, Tekkis PP, Fazio VW, et al. Adjuvant radiotherapy is associated with increased sexual dysfunction in male patients undergoing resection for rectal cancer: a predictive model. Ann Surg 2005;242:502–511.
20. Bretagnol F, Rullier E, George B, et al. Local therapy for rectal cancer: still controversial? Dis Colon Rectum 2007;50:523–533.
21. MERCURY Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ 2006;333: 779.
22. Bokey EL, Ojerskog B, Chapuis PH, et al. Local recurrence after curative excision of the rectum for cancer without adjuvant therapy: role of total anatomical dissection. Br J Surg 1999;86: 1164–1170.
23. Urban M, Rosen HR, Holbling N, et al. MR imaging for the preoperative planning of sphincter-saving surgery for tumors of the lower third of the rectum: use of intravenous and endorectal contrast materials. Radiology 2000;214:503–508.
24. Ueno H, Mochizuki H, Hashiguchi Y, et al. Preoperative parameters expanding the indication of sphincter preserving surgery in patients with advanced low rectal cancer. Ann Surg 2004;239: 34–42.
25. Syk E, Torkzad MR, Blomqvist L, et al. Radiological findings do not support lateral residual tumor as a major cause of local recurrence of rectal cancer. Br J Surg 2006;93:113–119.
26. Sugihara K, Kobayashi H, Kato T, et al. Indication and benefit of pelvic sidewall dissection for rectal cancer. Dis Colon Rectum 2006;49:1663–1672.

特集

直腸癌に対する腹腔鏡手術の問題点

直腸癌に対する腹腔鏡手術における縫合不全の危険因子
—縫合器，吻合器とその操作を中心に—

山岸　茂[*1]　藤井正一[*1]　樅山将士[*1]　永野靖彦[*1]
大田貢由[*2]　市川靖史[*2]　國崎主税[*1]　池　秀之[*1]
大木繁男[*2]　嶋田　紘[*2]

Risk Factors For Anastomotic Leakage After Laparoscopically Assisted Anterior Resection in Patients with Rectal Cancer: Yamagishi S[*1], Fujii S[*1], Momiyama M[*1], Nagano Y[*1], Ota M[*2], Ichikawa Y[*2], Kunisaki C[*1], Ike H[*1], Ohki S[*2] and Shimada H[*2] ([*1]Yokohama City University Medical Center, Gastroenterological Center, [*2]Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan)

Background: Anastomotic leakage is the most severe complication following rectal resection. The aim of this study was to evaluate risk factors of clinical anastomotic leakage after laparoscopically assisted anterior resection for rectal cancers.

Methods: A total of 65 consecutive operations involving anastomosis of the rectum performed from 1997 to 2006 were reviewed. The associations between clinical anastomotic leakage and 12 patient-, tumor-, surgical-, and device-related variables were studied by univariate and multivariate analysis. Result: The anastomotic leakage was seen in 12.3% (8 of 65). Univariate analysis showed that men ($p=0.046$) and a new dividing device ($p=0.046$) were significant factors of anastomotic leakage. The new dividing device remained significant after multivariate analysis (OR 7.00, p-value=0.036). In the former period, the new dividing device was the risk factor of anastomotic leakage, but not in the latter period. This study also revealed that multi-stapling was not a risk factor for anastomotic leakage.

Conclusion: In the laparoscopic surgery, because there are many types and use frequencies of the device, it is important to be well informed of the characteristic and safe directions, and to use an accustomed device.

Key words: Anastomotic leakage, Laparoscopically assisted surgery, Rectal cancer
Jpn J Cancer Clin **53**(2): 131～136, 2007

はじめに

大腸癌に対する腹腔鏡下手術は，1991年Jacobsの報告[1]以来，低侵襲性や整容性から急速に普及し，わが国では1992年から導入された．当初は早期がんが適応とされてきたが，進行がんにも適応が拡大され，現在では側方郭清が不必要な下部直腸癌にも適応とされている．直腸癌に対する腹腔鏡下手術の利点は，骨盤という限られた閉鎖腔の中でも，術者，助手全員が拡大視効果により解剖の把握が可能となることにより，安全に剥離，授動が行えることである[2]．しかし，肥満者や狭骨盤症例，8 cmを越える巨大腫瘍などでは操作性が制限される．このような症例は直腸の剥離操作は可能であるが，直腸切離前の肛門側腸管の洗浄および切離器械については，簡便で確実な腹腔鏡用器械が少なく，開腹術と比較して操作

*1 横浜市立大学附属市民総合医療センター消化器病センター
*2 横浜市立大学大学院医学研究科消化器病態外科学